GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010

GenSight Biologics Reports Full Year 2017 Financial Results

GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update

GenSight Biologics Reports its Cash Position as of September 30, 2017

GenSight Biologics to Attend Chardan Gene Therapy Conference

GenSight Biologics integrates the Enternext® PEA-PME 150 index

GenSight Biologics integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext indexes

GenSight Biologics Reports Interim Financial Results for the First Half of 2017

Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

GenSight Biologics launches a capital increase of approximately €20 million